What if psilocybin works about as well for depression as an SSRI?

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. If that thesis proves true, the arc of psilocybin, the most widely studied psychedelic of late, would broadly echo the trajectory of selective serotonin reuptake inhibitors, which were placed on a pedestal before real-world results tempered the enthusiasm. In 1989, New York magazine hailed Prozac as a wonder drug. A year later, Newsweek put the capsule on its cover and called it a breakthrough for depression. Fluoxetine, Prozac’s chemical name, had won FDA approval in 1987 and arrived in a landscape hungry for…

Source: Drug Discovery & Development